Immunovant Inc expected to post a loss of 39 cents a share - Earnings Preview

Immunovant

31/01/2023 14:52

* Immunovant Inc  IMVT.OQ   IMVT.O  is expected to show no
change
in quarterly revenue when it reports  results on February 2
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Immunovant Inc is
for a
loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunovant
Inc is
$18​, above​ its last closing price of $17.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.39       -0.39      -0.41     Missed  -4.8
 Jun. 30 2022  -0.39       -0.40      -0.35     Beat    11.6
 Mar. 31 2022  -0.35       -0.38      -0.41     Missed  -9.1​
 Dec. 31 2021  -0.32       -0.33      -0.36     Missed  -9.9
 ​​Sep.        -0.26       -0.28      -0.35     Missed  -25
 30 2021                                                
 Jun. 30 2021  -0.31       -0.31      -0.31     Met     0​
 Mar. 31 2021  -0.33       -0.33      -0.29     Beat    12.9
 Dec. 31 2020  -0.25       -0.26      -0.32     Missed  -24.1
 This summary was machine generated January 31 at 14:52 GMT.  All
figures in US dollars  unless otherwise stated